【常山药业:CSCJC3456片Ⅰ期临床试验首例受试者入组】常山药业公告,公司与控股子公司常山凯捷健生物药物研发(河北)有限公司开展的创新药CSCJC3456片Ⅰ期临床试验,于近日完成首例受试者入组。CSCJC3456片是由公司及常山凯捷健研发的靶向抗肿瘤药物,通过选择性抑制FGFR/KIT/RET/TRK等靶点而发挥抑制肿瘤细胞增殖、抑制新生血管生成、促进肿瘤凋亡的作用。临床前研究结果显示,CSCJC3456对多种癌症均显示良好的抗肿瘤作用,具有潜力在后续临床试验中展现出良好的治疗效果。

金融界
13 Feb
常山药业公告,公司与控股子公司常山凯捷健生物药物研发(河北)有限公司开展的创新药CSCJC3456片Ⅰ期临床试验,于近日完成首例受试者入组。CSCJC3456片是由公司及常山凯捷健研发的靶向抗肿瘤药物,通过选择性抑制FGFR/KIT/RET/TRK等靶点而发挥抑制肿瘤细胞增殖、抑制新生血管生成、促进肿瘤凋亡的作用。临床前研究结果显示,CSCJC3456对多种癌症均显示良好的抗肿瘤作用,具有潜力在后续临床试验中展现出良好的治疗效果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10